Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States)

A legfontosabb adatok

Ki végzi
Polares Medical SA
Hol
Atlanta, Cincinnati és The Bronx (Egyesült Államok)Mind a 3 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
15 fő, tervezett
Kezdés
2026. szept. 1.
Várható befejezés
2032. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • MR-ace Implant and Delivery System
A regiszteradat frissítve
2026. szeptember 1.

Ki vehet részt

Életkor
21 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 42 feltétel megnézéseKevesebb

Ki vehet részt

  • Patient has symptomatic moderate-to-severe to severe functional mitral regurgitation despite stable doses of maximally tolerated guideline directed medical therapy (GDMT) per the Local Heart Team; Note: In the 30 days prior to performing screening assessments, no new GDMT medications should be introduced and current doses should be stable (i.e. no decrease of > 50% or increase of > 100%) excluding diuretics. Any changes beyond this range would not be considered stable GDMT
  • Functional MR graded 3+ or higher (using a scale of 0 to 4+) by transthoracic echocardiography (TTE) within 60 days prior to study procedure as evaluated by the sponsor's Echo Core Lab
  • New York Heart Association (NYHA) Functional Class II, III or ambulatory IV heart failure
  • Patient must present with an STS Score less than 10% and deemed by the Local Heart Team to be at high risk but operable for mitral valve surgery
  • The Local Heart Team deems the patient unsuitable for commercially approved transcatheter mitral valve therapies
  • 21 years of age or older
  • Native mitral valve geometry and size is compatible with the Polares MRace system
  • Anatomy is suitable for transfemoral transseptal access with the Polares MRace system
  • Patient is willing to participate in study and provides signed IRB/EC-approved informed consent
  • Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits
  • Patient is approved by an independent Patient Eligibility Committee

Ki nem vehet részt

  • Previous mitral valve surgery or transcatheter mitral valve procedure
  • Prior orthotopic heart transplantation
  • Untreated Class I indication for pacing (CRT). Implant or revision of any pacing device < 30 days prior to intervention
  • Any untreated clinically significant coronary artery disease requiring revascularization. Coronary, carotid, or endovascular artery disease treated percutaneously < 30 days prior to study procedure. Cardiac surgery < 90 days prior to study procedure
  • Myocardial infarction requiring intervention < 30 days prior to study procedure
  • Active peptic ulcer or upper gastrointestinal bleeding < 90 days prior to study procedure
  • Stroke < 180 days prior to study procedure
  • Severe COPD requiring oral steroid therapy or oxygen therapy
  • Concurrent medical condition with a life expectancy of less than 2 years
  • Severe Right Ventricle (RV) dysfunction as per assessment by Local Heart Team or Eligibility Committee
  • Severe aortic stenosis or insufficiency
  • Barlow's disease
  • Active infection or endocarditis or infection requiring antibiotic therapy within 2 weeks of scheduled procedure
  • Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus. History of deep vein thrombosis (DVT) or pulmonary embolism within 6 months of the index procedure
  • Cardiogenic shock at time of enrolment. Hemodynamic instability requiring inotropic support or mechanical heart assistance
  • Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated; Note. Patient must be able to tolerate at least one antiplatelet medication AND one anticoagulant medication
  • Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial/procedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments
  • Patient is in need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
  • Patient is considered to be part of a vulnerable population, is under guardianship, or subject to any other medical, social or psychological conditions that preclude appropriate consent and follow-up
  • Echocardiographic parameters (any of the following, assessed by the Echo Core Lab); Left ventricular ejection fraction (LVEF) < 30%; Pulmonary artery systolic pressure (PASP) > 70mmHg or > 2/3 SBP (Systolic Blood Pressure); Left Ventricle End Diastolic Volume (LV EDV) > 200 mL; Left Ventricle End Systolic Volume (LV ESV) > 140 mL; Left Ventricle End Diastolic Diameter (LV EDD) > 70 mm; Left Ventricle End Systolic Diameter (LV ESD) > 55 mm
  • Severe renal insufficiency (creatinine > 3.0 mg/dL) or patient requiring dialysis
  • History of bleeding diathesis or coagulopathy or leukopenia (WBC < 3,000 mcL) or acute anemia (Hb < 9 g/dL) or thrombocytopenia (platelets < 50,000 cells mcL)
  • Severe tricuspid regurgitation
  • Severe mitral annulus calcification
  • Diseased mitral anterior and/or posterior leaflet, such as flail, / prolapse, or/ heavy moderate to severe calcification
  • Presence of an implanted vena cava filter or any other device (e.g. ASD closure device) that may interfere with femoral vein access or delivery system access to the mitral valve
  • Contraindication for transesophageal echocardiography (TEE) or MDCT scan
  • Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis)
  • Pregnancy or breastfeeding at time of enrolment with a positive pregnancy test within 14 days of study procedure
  • Company employees or their immediate family members
  • Patient is participating in another clinical study for which follow-up is currently ongoing

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Emory MidtownAtlanta, Egyesült ÁllamokContact: Elizabeth CharlesRésztvevőt keres
  • The Lindner Research Center at the Christ HospitalCincinnati, Egyesült ÁllamokContact: Katy FischesserToborzás még nem indult
  • Montefiore Medical CenterThe Bronx, Egyesült ÁllamokContact: Tammy GuzmanToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this early feasibility clinical trial is to learn if the device MR-ace Implant and Delivery System works in patients with moderate or severe mitral valve regurgitation. It will also learn about the safety of the device MR-ace Implant and Delivery System. The main questions it aims to answer are:

A teljes eredeti leírásKevesebb

Does implanting the MR-ace device reduce the symptoms of mitral regurgitation? Does the device reduce the the leak through your mitral valve?

Participants will:

Be implanted with the device Visit the clinic for checkups and tests at 30 days, 6 months, 12 months, and 2, 3, 4 and 5 years following your procedure Complete a quality of life survey

A vizsgálat csoportja

  • TreatmentA vizsgált kezelés

    treatment with the study device

    Kezelés: MR-ace Implant and Delivery System

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Early Feasibility Experience of Posterior Leaflet Replacement to Reduce Mitral Regurgitation Using the MRace Implant (United States)
A regiszteradat frissítve
2026. szeptember 1.